Ombitasvir is primarily used in the treatment of chronic hepatitis C virus (HCV) infection. It is often combined with other antiviral agents, such as paritaprevir and ritonavir, to enhance its effectiveness. This combination therapy targets specific proteins in the HCV, preventing the virus from replicating and spreading in the body. It is particularly effective for patients with HCV genotypes 1 and 4. The use of Ombitasvir has shown significant success in achieving sustained virologic response, which means the virus becomes undetectable in the blood after treatment. This helps in reducing liver damage, improving liver function, and lowering the risk of complications like cirrhosis and liver cancer. It is administered orally, making it convenient for patients to adhere to the treatment regimen.